OPTN News and Press, OptiNose Inc. From 05/11/23

2023-05-11 17:57:10 ET OptiNose Inc. (OPTN) Q1 2023 Results Conference Call May 11, 2023 08:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Canto...

2023-05-11 07:02:23 ET OptiNose press release ( NASDAQ: OPTN ): Q1 GAAP EPS of -$0.17. Revenue of $11.85M (-19.7% Y/Y). For further details see: OptiNose GAAP EPS of -$0.17, revenue of $11.85M

Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call a...

2023-05-04 09:16:53 ET The U.S. Food and Drug Administration (FDA) accepted for review Optinose's ( NASDAQ: OPTN ) application seeking expanded approval of Xhance to treat chronic rhinosinusitis (CR). CR can occur due to an infection by growth in the sinuses (nasal polyps) or ...

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment ...

YARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2023 and corporate updates, before...

2023-03-07 14:22:05 ET OptiNose, Inc. (OPTN) Q4 2022 Earnings Call March 7, 2023 8:00 PM ET Company Participants Jonathan Neely - VP, IR and Business Development Joe Scodari - Chairman Ramy Mahmoud - Chief Executive Officer Paul Spence - Chief Commercial Offi...

2023-03-07 07:03:46 ET OptiNose press release ( NASDAQ: OPTN ): Q4 GAAP EPS of -$0.17 in-line. Revenue of $20.86M (-7.3% Y/Y) beats by $0.17M . The company expects XHANCE net revenues for the full year of 2023 to be between $62.0 to $68.0 million. XHANCE net revenu...

Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasa...

YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2022 and corporate updates, befo...